D Santos-García1, T de Deus Fonticoba2, E Suárez Castro2, A Aneiros Díaz2, C Cores Bartolomé3, M J Feal Panceiras3, J M Paz González3, L Valdés Aymerich3, J M García Moreno4, M Blázquez Estrada5, S Jesús6, P Mir6, M Aguilar7, L L Planellas8, J García Caldentey9, N Caballol10, I Legarda11, I Cabo López12, L López Manzanares13, M A Ávila Rivera14, M J Catalán15, L M López Díaz16, C Borrué17, M Álvarez Sauco18, L Vela19, E Cubo20, J C Martínez Castrillo21, P Sánchez Alonso22, M G Alonso Losada23, N López Ariztegui24, I Gastón25, B Pascual-Sedano26, M Seijo12, J Ruíz Martínez27, C Valero28, M Kurtis29, J González Ardura30, C Prieto Jurczynska31, P Martinez-Martin32. 1. CHUAC, Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain. Electronic address: diegosangar@yahoo.es. 2. Hospital Arquitecto Marcide y Hospital Naval, Complejo Hospitalario Universitario de Ferrol (CHUF), Ferrol, A Coruña, Spain. 3. CHUAC, Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain. 4. Hospital Universitario Virgen Macarena, Sevilla, Spain. 5. Hospital Universitario Central de Asturias, Oviedo, Spain. 6. Hospital Universitario Virgen del Rocío, Sevilla, Spain. 7. Hospital Universitari Mutua de Terrassa, Terrassa, Barcelona, Spain. 8. Hospital Clínic de Barcelona, Barcelona, Spain. 9. Centro Neurológico Oms 42, Palma de Mallorca, Spain. 10. Consorci Sanitari Integral, Hospital Moisés Broggi, Sant Joan Despí, Barcelona, Spain. 11. Hospital Universitario Son Espases, Palma de Mallorca, Spain. 12. Complejo Hospitalario Universitario de Pontevedra (CHOP), Pontevedra, Spain. 13. Hospital La Princesa, Madrid, Spain. 14. Consorci Sanitari Integral, Hospital General de L'Hospitalet, L'Hospitalet de Llobregat, Barcelona, Spain. 15. Hospital Universitario Clínico San Carlos, Madrid, Spain. 16. Complejo Hospitalario Universitario de Ourense (CHUO), Ourense, Spain. 17. Hospital Infanta Sofía, Madrid, Spain. 18. Hospital General Universitario de Elche, Elche, Spain. 19. Fundación Hospital de Alcorcón, Madrid, Spain. 20. Complejo Asistencial Universitario de Burgos, Burgos, Spain. 21. Hospital Universitario Ramón y Cajal, Madrid, Spain. 22. Hospital Universitario Puerta de Hierro, Madrid, Spain. 23. Hospital Álvaro Cunqueiro, Complejo Hospitalario Universitario de Vigo (CHUVI), Vigo, Spain. 24. Complejo Hospitalario de Toledo, Toledo, Spain. 25. Complejo Hospitalario de Navarra, Pamplona, Spain. 26. Hospital de Sant Pau, Barcelona, Spain; Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Spain; Faculty of Health Sciences, Universitat Oberta de Catalunya (UOC), Barcelona, Spain. 27. Hospital Universitario Donostia, San Sebastián, Spain. 28. Hospital Arnau de Vilanova, Valencia, Spain. 29. Hospital Ruber Internacional, Madrid, Spain. 30. Hospital Universitario Lucus Augusti (HULA), Lugo, Spain. 31. Hospital Rey Juan Carlos, Madrid, Spain. 32. Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Spain; CIBERNED, Instituto de Salud Carlos III, Madrid. COPPADIS Study Group, Spain.
Abstract
BACKGROUND: The role of subthreshold depression (subD) in Parkinson's Disease (PD) is not clear. The present study aimed to compare the quality of life (QoL) in PD patients with subD vs patients with no depressive disorder (nonD). Factors related to subD were identified. MATERIAL AND METHODS: PD patients and controls recruited from the COPPADIS cohort were included. SubD was defined as Judd criteria. The 39-item Parkinson's disease Questionnaire (PDQ-39) and the EUROHIS-QOL 8-item index (EUROHIS-QOL8) were used to assess QoL. RESULTS: The frequency of depressive symptoms was higher in PD patients (n = 694) than in controls (n = 207) (p < 0.0001): major depression, 16.1% vs 7.8%; minor depression, 16.7% vs 7.3%; subD, 17.4% vs 5.8%. Both health-related QoL (PDQ-39; 18.1 ± 12.8 vs 11.6 ± 10; p < 0.0001) and global QoL (EUROHIS-QOL8; 3.7 ± 0.5 vs 4 ± 0.5; p < 0.0001) were significantly worse in subD (n = 120) than nonD (n = 348) PD patients. Non-motor Symptoms Scale (NMSS) total score was higher in subD patients (45.9 ± 32 vs 29.1 ± 25.8;p < 0.0001). Non-motor symptoms burden (NMSS;OR = 1.019;95%CI 1.011-1.028; p < 0.0001), neuropsychiatric symptoms (NPI; OR = 1.091; 95%CI 1.045-1.139; p < 0.0001), impulse control behaviors (QUIP-RS; OR = 1.035; 95%CI 1.007-1063; p = 0.013), quality of sleep (PDSS; OR = 0.991; 95%CI 0.983-0.999; p = 0.042), and fatigue (VAFS-physical; OR = 1.185; 95%CI 1.086-1.293; p < 0.0001; VAFS-mental; OR = 1.164; 95%CI 1.058-1.280; p = 0.0001) were related to subD after adjustment to age, disease duration, daily equivalent levodopa dose, motor status (UPDRS-III), and living alone. CONCLUSIONS: SubD is a frequent problem in patients with PD and is more prevalent in these patients than in controls. QoL is worse and non-motor symptoms burden is greater in subD PD patients.
BACKGROUND: The role of subthreshold depression (subD) in Parkinson's Disease (PD) is not clear. The present study aimed to compare the quality of life (QoL) in PDpatients with subD vs patients with no depressive disorder (nonD). Factors related to subD were identified. MATERIAL AND METHODS:PDpatients and controls recruited from the COPPADIS cohort were included. SubD was defined as Judd criteria. The 39-item Parkinson's disease Questionnaire (PDQ-39) and the EUROHIS-QOL 8-item index (EUROHIS-QOL8) were used to assess QoL. RESULTS: The frequency of depressive symptoms was higher in PDpatients (n = 694) than in controls (n = 207) (p < 0.0001): major depression, 16.1% vs 7.8%; minor depression, 16.7% vs 7.3%; subD, 17.4% vs 5.8%. Both health-related QoL (PDQ-39; 18.1 ± 12.8 vs 11.6 ± 10; p < 0.0001) and global QoL (EUROHIS-QOL8; 3.7 ± 0.5 vs 4 ± 0.5; p < 0.0001) were significantly worse in subD (n = 120) than nonD (n = 348) PDpatients. Non-motor Symptoms Scale (NMSS) total score was higher in subD patients (45.9 ± 32 vs 29.1 ± 25.8;p < 0.0001). Non-motor symptoms burden (NMSS;OR = 1.019;95%CI 1.011-1.028; p < 0.0001), neuropsychiatric symptoms (NPI; OR = 1.091; 95%CI 1.045-1.139; p < 0.0001), impulse control behaviors (QUIP-RS; OR = 1.035; 95%CI 1.007-1063; p = 0.013), quality of sleep (PDSS; OR = 0.991; 95%CI 0.983-0.999; p = 0.042), and fatigue (VAFS-physical; OR = 1.185; 95%CI 1.086-1.293; p < 0.0001; VAFS-mental; OR = 1.164; 95%CI 1.058-1.280; p = 0.0001) were related to subD after adjustment to age, disease duration, daily equivalent levodopa dose, motor status (UPDRS-III), and living alone. CONCLUSIONS: SubD is a frequent problem in patients with PD and is more prevalent in these patients than in controls. QoL is worse and non-motor symptoms burden is greater in subD PDpatients.
Authors: Sneha Mantri; Lana M Chahine; Karina Nabieva; Robert Feldman; Andrew Althouse; Benjamin Torsney; Steven M Albert; Catherine Kopil; Connie Marras Journal: Mov Disord Clin Pract Date: 2021-10-28
Authors: Carmen M Labandeira; Maria G Alonso Losada; Rosa Yáñez Baña; Maria I Cimas Hernando; Iria Cabo López; Jose M Paz González; Maria J Gonzalez Palmás; Cristina Martínez Miró; Diego Santos García Journal: Adv Ther Date: 2021-09-15 Impact factor: 3.845